Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

19.04.22	Lilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement (PR Newswire)
19.04.22	Form 4 59478 (RSS)
14.04.22	Pharmaindustrie: Angebot von Corona-Impfstoffen übersteigt Nachfrage (AWP)
13.04.22	Erste Schätzungen: Eli Lilly and verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net)
11.04.22	Lilly's Lebrikizumab - Corticosteroids Show Improvements In Disease Severity For Atopic Dermatitis (RTTNews)
11.04.22	Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis (PR Newswire)
07.04.22	Form 4 59478 (RSS)
01.04.22	Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress (PR Newswire)
29.03.22	Form 4 59478 (RSS)
28.03.22	Innovent Biologics, Lilly Expand Partnership In Oncology (RTTNews)
28.03.22	Innovent and Lilly Expand Strategic Partnership in Oncology (PR Newswire)
26.03.22	Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies (PR Newswire)
26.03.22	Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies (PR Newswire)
24.03.22	Eli Lilly: FDA Issues CRL For BLA For Sintilimab; Unable To Approve Application In Its Current Form (RTTNews)
24.03.22	Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer (PR Newswire)
18.03.22	Statement of changes in beneficial ownership of securities (RSS)
17.03.22	Form 4 59478 (RSS)
16.03.22	Eli Lilly: EMPA-KIDNEY Trial Shows Efficacy For Jardiance At Early Stage; Trial To Stop (RTTNews)
16.03.22	Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease (PR Newswire)
14.03.22	Boeing : Arajet Orders 20 737 MAX Aircraft (RTTNews)
08.03.22	Lilly Announces Details of Presentations at 2022 American Association for Cancer Research (AACR) (PR Newswire)
07.03.22	Form 4 59478 (RSS)
03.03.22	Lilly to Participate in Barclays Global Healthcare Conference (PR Newswire)
01.03.22	Eli Lilly Says Jardiance Provides Significant Benefit In Adults Following Acute Heart Failure (RTTNews)
01.03.22	Jardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial (PR Newswire)
28.02.22	Lilly to Participate in Cowen Health Care Conference (PR Newswire)
28.02.22	Biotech Stocks Facing FDA Decision In March 2022 (RTTNews)
25.02.22	FDA Approves Jardiance To Treat Adults With Heart Failure (RTTNews)
24.02.22	US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction (PR Newswire)
24.02.22	Form 4 59478 (RSS)
22.02.22	Lilly Launches Institute For Genetic Medicine; Invests $700 Mln (RTTNews)
22.02.22	Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site (PR Newswire)
18.02.22	Nearly Two-Thirds of Patients Respond to Mirikizumab Treatment at 12 Weeks in Lilly's First-in-Class Ulcerative Colitis Phase 3 LUCENT-1 Study (PR Newswire)
16.02.22	Lilly and Breast Cancer Advocacy Organizations Collaborate to Drive Awareness of the Complexities of Early Breast Cancer and the Risk of Recurrence (PR Newswire)
11.02.22	FDA Issues Emergency Use Authorization For Eli Lilly's Covid-19 Treatment (RTTNews)
11.02.22	Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19 (PR Newswire)
11.02.22	FDA Panel Votes Against Lilly's Lung Cancer Drug For China-only Trial (RTTNews)
11.02.22	Form 4 59478 (RSS)
11.02.22	Lilly Reaches Deal With U.S. To Supply Up To 600,000 Doses Of Bebtelovimab For COVID-19 Treatment (RTTNews)
10.02.22	Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options (PR Newswire)
10.02.22	Form SC 13G 59478 (RSS)
03.02.22	Eli Lilly Q4 Results Top Estimates; Reaffirms FY22 Outlook (RTTNews)
03.02.22	Eli Lilly And Co. Profit Declines In Q4 (RTTNews)
03.02.22	Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients (PR Newswire)
02.02.22	UNICEF and Lilly Collaborate to Help Improve Health Outcomes for 10 Million Children and Adolescents (PR Newswire)
02.02.22	Ausblick: Eli Lilly and präsentiert Quartalsergebnisse (finanzen.net) Das sind die Prognosen der Analysten für die anstehende Eli Lilly and-Bilanz.» mehr
01.02.22	Lilly to Participate in Guggenheim Oncology Conference (PR Newswire)
29.01.22	Eli Lilly To Invest $1 Bln To Build New Plant In Concord (RTTNews)
28.01.22	Lilly announces $1 billion investment in new manufacturing facility in North Carolina (PR Newswire)
28.01.22	Lilly To Discontinue Phase 3 Development Program For OLUMIANT In Lupus - Quick Facts (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

16:21		Bayer-Aktie in Grün: Weiterer Studienerfolg
16:19		Pharmakonzern STADA vor milliardenschwerem Börsengang
16:13		Novartis-Aktie höher: Novartis kooperiert mit Light Horse Therapeutics
15:59		Handel in Europa: Euro STOXX 50 fester
15:59		STOXX 50 aktuell: So performt der STOXX 50 am Nachmittag
15:59		Angespannte Stimmung in Frankfurt: LUS-DAX fällt nachmittags
15:59		Starker Wochentag in Zürich: SMI nachmittags im Plus
15:58		Aktienempfehlung Novartis-Aktie: Goldman Sachs Group Inc. bewertet Anteilsschein in neuer Analyse

16:21

Bayer-Aktie in Grün: Weiterer Studienerfolg

16:19

Pharmakonzern STADA vor milliardenschwerem Börsengang

16:13

Novartis-Aktie höher: Novartis kooperiert mit Light Horse Therapeutics

15:59

Handel in Europa: Euro STOXX 50 fester

15:59

STOXX 50 aktuell: So performt der STOXX 50 am Nachmittag

15:59

Angespannte Stimmung in Frankfurt: LUS-DAX fällt nachmittags

15:59

Starker Wochentag in Zürich: SMI nachmittags im Plus

15:58

Aktienempfehlung Novartis-Aktie: Goldman Sachs Group Inc. bewertet Anteilsschein in neuer Analyse

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	30.38	2.91 %	K V
Part Grp Hldg	1’332.50	2.58 %	K V
Roche Hldg G	272.30	2.02 %	K V
Givaudan	3’940.00	1.49 %	K V
Novartis	91.71	0.82 %	K V
Geberit	502.80	-0.59 %	K V
CieFinRichemont	140.05	-0.64 %	K V
Zurich Insur Gr	542.00	-0.95 %	K V
Swiss Re	133.40	-1.04 %	K V
Kuehne+Nagel Int	203.00	-2.12 %	K V

Nachrichten zu Eli Lilly

Aktien Top/Flop

Eli Lilly Peer Group Nachrichten

Meistgelesene Nachrichten